In vivo selection of hematopoietic progenitor cells and temozolomide dose intensification in rhesus macaques through lentiviral transduction with a drug resistance gene.
about
Towards in vivo amplification: Overcoming hurdles in the use of hematopoietic stem cells in transplantation and gene therapyHematopoietic stem cell gene therapy:assessing the relevance of preclinical modelsModified multipotent stromal cells with epidermal growth factor restore vasculogenesis and blood flow in ischemic hind-limb of type II diabetic miceEngineered drug-resistant immunocompetent cells enhance tumor cell killing during a chemotherapy challenge.Efficient selection of genetically modified human T cells using methotrexate-resistant human dihydrofolate reductase.Cell- and gene-based therapeutic approaches for neurological deficits in mucopolysaccharidosesFeline leukemia virus integrase and capsid packaging functions do not change the insertion profile of standard Moloney retroviral vectorsEfficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates.In vivo enrichment of genetically manipulated platelets corrects the murine hemophilic phenotype and induces immune tolerance even using a low multiplicity of infectionLarge animal models of hematopoietic stem cell gene therapy.Repetitive busulfan administration after hematopoietic stem cell gene therapy associated with a dominant HDAC7 clone in a nonhuman primate.Stem cell selection in vivo using foamy vectors cures canine pyruvate kinase deficiency.Genetic modification of mouse bone marrow by lentiviral vector-mediated delivery of hypoxanthine-Guanine phosphoribosyltransferase short hairpin RNA confers chemoprotection against 6-thioguanine cytotoxicity.Contributions of gene marking to cell and gene therapies.Imaging stem cell-derived persistent foci after in vivo selection of lentiviral MGMT-P140K transduced murine bone marrow cells.Differential Secondary Reconstitution of In Vivo-Selected Human SCID-Repopulating Cells in NOD/SCID versus NOD/SCID/γ chain Mice.Foamy viral vector integration sites in SCID-repopulating cells after MGMTP140K-mediated in vivo selectionTreatment of a solid tumor using engineered drug-resistant immunocompetent cells and cytotoxic chemotherapy.Chemoselection of allogeneic HSC after murine neonatal transplantation without myeloablation or post-transplant immunosuppression.Development of gene therapy for blood disorders: an update.Efficiency and safety of O⁶-methylguanine DNA methyltransferase (MGMT(P140K))-mediated in vivo selection in a humanized mouse modelDevelopment of gene therapy for thalassemia.Which drug or drug delivery system can change clinical practice for brain tumor therapy?The Ongoing Challenge of Hematopoietic Stem Cell-Based Gene Therapy for β-Thalassemia.Chemoprotection in brain tumor patients: another success for stem cell gene therapy.Overexpression of NAC1 confers drug resistance via HOXA9 in colorectal carcinoma cells.Gene Addition Strategies for β-Thalassemia and Sickle Cell Anemia.A Combined In Vivo HSC Transduction/Selection Approach Results in Efficient and Stable Gene Expression in Peripheral Blood Cells in Mice.Integrating HDAd5/35++ Vectors as a New Platform for HSC Gene Therapy of Hemoglobinopathies.
P2860
Q26771159-09980A84-C7A6-4BF3-8873-9CA46907DEC3Q26859147-1AEA1186-11FA-4F1B-B60D-9A8E015DEBFAQ30503408-12E65B93-FA8C-4B86-9DD0-347A0F1F44D6Q33615816-78FC0E49-0139-4815-BA94-B711BC1A6683Q33637665-7B3626BA-661E-4C32-94B4-7D9B8D6C71E8Q33692991-33D8F67E-3302-497C-8ADC-215DA2A105F1Q33905768-9A6CE2D7-7C4A-4894-9681-B6C656875483Q33968014-906DD22D-7569-49AE-A11D-C9D154814305Q34021880-51B7BE79-B9E2-4F2E-AAC8-458CCDEE2626Q34039922-3F08590D-4C8A-4BB2-83D9-8324380D4E6FQ34123262-3B09D348-E2DC-4823-AEB2-C163C38C7321Q34428276-B8A8B9A2-6263-45B5-BEBE-E1F9EEB5C31EQ35009319-F26629D0-049C-4A11-8378-FC4B69881D88Q35059829-A9676DF5-1B12-459B-BD38-CA6703B02783Q35086091-57DDC315-F758-4D89-ABDC-7E6DDA8BF8FDQ35430705-162BA49F-8605-4A2B-AAD5-667D2706EF61Q35812028-A2651B4D-7519-4955-9AE5-FA845830D838Q36114222-B847CC93-67B5-443D-BE39-1EF3E1B9A2DCQ36401055-942D0E80-C39D-460E-89B8-589DFD8BB0B0Q37132611-170F81BA-8DFB-42D4-9CEC-9C2C7BC3AE92Q37580086-02CC9994-FD3F-4BC6-A00B-4309667417CFQ38057725-D76B381A-3516-4C33-AB3A-464E3C7EC392Q38090394-3BC0E2D3-1AFC-4875-BC1F-1B2E0ADE4E12Q39749114-579635CF-1BA9-4C1B-ABC8-CAFF1B6D8B9EQ42226731-50F0CEEE-96F7-4134-838E-F56E3F45E302Q42546855-F5A5C2C8-3441-40DD-BE8E-715BD1DD2D59Q45874313-97B9C76A-4918-4115-B80C-A00156051733Q47162946-CA98537A-9F1C-4252-9C7B-5852ED1D273BQ55333613-82C89126-480B-428B-8333-8F21C9250BA7
P2860
In vivo selection of hematopoietic progenitor cells and temozolomide dose intensification in rhesus macaques through lentiviral transduction with a drug resistance gene.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
In vivo selection of hematopoi ...... n with a drug resistance gene.
@en
In vivo selection of hematopoi ...... n with a drug resistance gene.
@nl
type
label
In vivo selection of hematopoi ...... n with a drug resistance gene.
@en
In vivo selection of hematopoi ...... n with a drug resistance gene.
@nl
prefLabel
In vivo selection of hematopoi ...... n with a drug resistance gene.
@en
In vivo selection of hematopoi ...... n with a drug resistance gene.
@nl
P2093
P2860
P356
P1476
In vivo selection of hematopoi ...... n with a drug resistance gene.
@en
P2093
Allen Krouse
Andre Larochelle
Brian P Sorrentino
Clinton Stewart
Derek Persons
Elizabeth Kang
Joshua R Clevenger
Mark Metzger
Natalia A Loktionova
Nora Naumann
P2860
P304
P356
10.1172/JCI37506
P407
P577
2009-06-08T00:00:00Z